Drug giant Pfizer is reporting that preliminary data from its SUN 1087 trial indicates that the multi-targeted receptor tyrosine kinase (RTK) inhibitor Stutent (sunitinib malate), when combined with erlotinib (Tarceva) does not improve overall survival of patients with previously treated non-small cell lung cancer when compared to patients on erlotinib only. While the combination did show some improvement in progression-free survival for this patient population, the study's primary endpoint was overall survival.
Sutent is currently FDA approved for two indications: for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, and for the treatment of advanced renal cell carcinoma.
CANCER TYPE(S)
Non-small cell lung cancer
TREATMENT TYPE(S)
Targeted therapy
By Ross Bonander
Source
Medical News Today
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
